NCT05733611 2026-02-02
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Replimune Inc.
Phase 2 Terminated
Clinical Trials
57 trialsNCT06509906 2025-12-18
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
EMD Serono
Phase 1 Terminated
NCT05200364 2025-09-22
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
Sutro Biopharma, Inc.
Phase 1 Terminated
NCT05589597 2025-08-22
AUDREY
Enterome
Phase 1/2 Terminated
NCT05330429 2025-07-01
ELEVATE CRC
Gilead Sciences
Phase 2 Terminated
NCT04732286 2025-05-08
A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
Hoffmann-La Roche
Phase 3 Terminated
NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
NCT04952753 2025-03-26
daNIS-3
Novartis
Phase 2 Terminated
NCT04421378 2024-12-16
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Karyopharm Therapeutics Inc
Phase 1/2 Terminated
NCT03329248 2024-12-12
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT05824559 2024-11-21
ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer
MEI Pharma, Inc.
Phase 1 Terminated
NCT06448364 2024-11-06
LTbR
Pfizer
Phase 1 Terminated
NCT04325698 2024-10-01
A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC
Pfizer
Phase 3 Terminated
NCT03586869 2024-08-27
QUILT-3.080: NANT Pancreatic Cancer Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03387085 2024-08-09
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03387111 2024-08-05
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03136406 2024-06-11
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03387098 2024-05-22
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT05648006 2024-04-30
First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer
Binhui Biopharmaceutical Co., Ltd.
Phase 2 Terminated
NCT04681677 2024-04-26
IORT
Xoft, Inc.
Phase 2 Terminated
NCT01133990 2023-11-07
FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
Eisai Inc.
Phase 1/2 Terminated
NCT03555149 2023-11-07
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
Hoffmann-La Roche
Phase 1/2 Terminated
NCT04861948 2022-10-04
IBI188 Combination Therapy in Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Terminated
NCT03690739 2022-02-24
Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer
AGO Research GmbH
Phase 3 Terminated
NCT03176264 2021-10-12
PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer
Novartis
Phase 1 Terminated
NCT03368859 2021-02-09
A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
AbbVie
Phase 2 Terminated
NCT00536939 2020-09-24
Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer
Eli Lilly and Company
Phase 2 Terminated
NCT02648711 2020-05-28
Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
Lumos Pharma
Phase 1 Terminated
NCT02141295 2020-03-25
McCAVE
Hoffmann-La Roche
Phase 2 Terminated
NCT02414165 2020-02-07
Toca5
Tocagen Inc.
Phase 2/3 Terminated
NCT00281528 2019-11-22
Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
Celgene
Phase 2 Terminated
NCT02664961 2019-07-23
Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
Tracon Pharmaceuticals Inc.
Phase 2 Terminated
NCT00642603 2018-03-29
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT02047214 2018-01-31
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
Cortice Biosciences, Inc.
Phase 2 Terminated
NCT00369070 2018-01-04
A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC
Amgen
Phase 2 Terminated
NCT01765582 2017-09-18
STEAM
Hoffmann-La Roche
Phase 2 Terminated
NCT00486759 2017-07-25
A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
Hoffmann-La Roche
Phase 3 Terminated
NCT01383148 2017-01-05
TIME
Transgene
Phase 2/3 Terminated
NCT00642824 2016-11-02
A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Hoffmann-La Roche
Phase 2 Terminated
NCT00845910 2016-11-02
A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT00404703 2016-08-24
A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT01937715 2016-08-18
A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
Pfizer
Phase 1/2 Terminated
NCT02060955 2016-06-06
Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan
CytoVac A/S
Phase 2 Terminated
NCT00766246 2016-04-19
Phase II Avastin Trial for Stage IIIB/IV NSCLC
Pharmatech
Phase 2 Terminated
NCT00356681 2015-10-15
A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer
Amgen
Phase 2 Terminated
NCT00850577 2015-10-12
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 2 Terminated
NCT00576901 2014-08-11
A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.
Hoffmann-La Roche
Phase 2 Terminated
NCT02079519 2014-07-08
A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma
Hoffmann-La Roche
Phase 2 Terminated
NCT00609622 2012-10-11
Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer
Pfizer
Phase 2 Terminated
NCT00326911 2011-05-25
Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer
Eli Lilly and Company
Phase 2 Terminated